Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Special Issue: Current evidence and perspectives for hypertension management in Asia
  • Published:

Associations between IGFBP1 gene polymorphisms and the risk of preeclampsia and fetal growth restriction

Hypertension Research volume 46, pages 2070–2084 (2023)Cite this article

A Comment to this article was published on 15 August 2023

Abstract

IGFBP1 plays a critical role in the pathogenesis of preeclampsia (PE), but the association between single nucleotide polymorphism (SNP) of IGFBP1 gene and PE susceptibility has not yet been determined. In our study, 229 women with PE and 361 healthy pregnant (non-PE) women were enrolled to investigate its association via TaqMan genotyping assay. In addition, the protein levels of IGFBP1 under different genotypes were explored by ELISA and IHC. We found that IGFBP1 SNP rs1065780A > G was associated with an decreased risk for PE. Women with GG (P = 0.027) or AG (Padj. = 0.023) genotype manifested a significantly lower risk for PE compared to women with AA genotype. In PE group, women carrying G allele exhibited greater fetal birth weight, lower diastolic BP, and lower levels of ALT and AST. The G genotype was found significantly less frequently in the severe preeclampsia (SPE) group than in the non-PE group (GG vs. AA, P = 0.007; G vs. A, P = 0.006). Additionally, women in the PE group who experienced fetal growth restriction (FGR) reflected a lower level of the allele G than did the non-FGR group (P = 0.032); this was not the case for the non-PE group.Rs1065780A>G elevated IGFBP1 protein level in plasma and decidua in PE group. In conclusion Chinese Han women with the SNP IGFBP1 rs1065780 occupied by G exhibited a lower risk of developing PE relative to women with the A genotype and augured for improved pregnancy outcomes through elevation of IGFBP1 protein level.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15:275–89.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia prevalence, risk factors, and pregnancy outcomes in Sweden and China. JAMA Netw Open. 2021;4:e218401.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124:1094–112.

    Article  CAS  PubMed  Google Scholar 

  4. Sitar T, Popowicz GM, Siwanowicz I, Huber R, Holak TA. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci USA. 2006;103:13028–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 1997;8:45–62.

    Article  CAS  PubMed  Google Scholar 

  6. Han VK, Bassett N, Walton J, Challis JR. The expression of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab. 1996;81:2680–93.

    CAS  PubMed  Google Scholar 

  7. Hills FA, Elder MG, Chard T, Sullivan MHF. Regulation of human villous trophoblast by insulin-like growth factors and insulin-like growth factor-binding protein-1. J Endocrinol. 2004;183:487–96.

    Article  CAS  PubMed  Google Scholar 

  8. Yu J, Iwashita M, Kudo Y, Takeda Y. Phosphorylated insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1 stimulates IGF-I-induced amino acid uptake by cultured trophoblast cells. Growth Horm IGF Res. 1998;8:65–70.

    Article  CAS  PubMed  Google Scholar 

  9. Li X, Li C, Wang Y, Cai J, Zhao L, Su Z, et al. IGFBP1 inhibits the invasion, migration, and apoptosis of HTR-8/SVneo trophoblast cells in preeclampsia. Hypertens Pregnancy. 2022;41:53–63.

    Article  PubMed  Google Scholar 

  10. Dunn CL, Kelly RW, Critchley HOD. Decidualization of the human endometrial stromal cell: an enigmatic transformation. Reprod Biomed Online. 2003;7:151–61.

    Article  PubMed  Google Scholar 

  11. Garrido-Gomez T, Dominguez F, Quiñonero A, Diaz-Gimeno P, Kapidzic M, Gormley M, et al. Defective decidualization during and after severe preeclampsia reveals a possible maternal contribution to the etiology. Proc Natl Acad Sci USA. 2017;114:E8468–E8477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway. J Clin Endocrinol Metab. 2001;86:2484–93.

    CAS  PubMed  Google Scholar 

  13. Garrido-Gomez T, Quiñonero A, Dominguez F, Rubert L, Perales A, Hajjar KA, et al. Preeclampsia: a defect in decidualization is associated with deficiency of Annexin A2. Am J Obstet Gynecol. 2020;222:376.e1–376.e17.

    Article  CAS  PubMed  Google Scholar 

  14. Vatten LJ, Nilsen TIL, Juul A, Jeansson S, Jenum PA, Eskild A. Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia. Eur J Endocrinol. 2008;158:101–5.

    Article  CAS  PubMed  Google Scholar 

  15. Liao S, Vickers MH, Taylor RS, Jones B, Fraser M, McCowan LME, et al. Maternal serum IGF-1, IGFBP-1 and 3, and placental growth hormone at 20 weeks’ gestation in pregnancies complicated by preeclampsia. Pregnancy Hypertens. 2017;10:149–54.

    Article  PubMed  Google Scholar 

  16. van der Kaay D, Deal C, de Kort S, Willemsen R, Leunissen R, Ester W, et al. Insulin-like growth factor-binding protein-1: serum levels, promoter polymorphism, and associations with components of the metabolic syndrome in short subjects born small for gestational age. J Clin Endocrinol Metab. 2009;94:1386–92.

    Article  PubMed  Google Scholar 

  17. Oh SY, Shin A, Kim S-G, Hwang J-A, Hong SH, Lee Y-S, et al. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX. Oncotarget. 2016;7:31204–14.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Fang Z, Yang S, Zhu L, Li Y, Chen Y, Jin Y, et al. Association study of IGFBP1 and IGFBP3 polymorphisms with hypertension and cardio-cerebral vascular diseases in a Chinese Han population. Oncotarget. 2017;8:77836–45.

    Article  PubMed  PubMed Central  Google Scholar 

  19. McGinnis R, Steinthorsdottir V, Williams NO, Thorleifsson G, Shooter S, Hjartardottir S, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat Genet. 2017;49:1255–60.

    Article  CAS  PubMed  Google Scholar 

  20. Moses EK, Johnson MP, Tømmerdal L, Forsmo S, Curran JE, Abraham LJ, et al. Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol. 2008;198:336.e331–336.e335.

    Article  Google Scholar 

  21. Metz TD, Nelson LM, Stoddard GJ, Silver RM. FOXP3 gene polymorphisms in preeclampsia. Am J Obstet Gynecol. 2012;206:165.e161–165.e166.

    Article  Google Scholar 

  22. American College of Obstetricians and Gynecologists (ACOG). Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:e237–e260.

    Article  Google Scholar 

  23. Wang H, Ma L, Pan X, Du Z, Chen Y. Novel associations of SNPs MYLIP rs3757354 and ABCA1 2230806 gene with early-onset-preeclampsia: A case-control candidate genetic study. Pregnancy Hypertens. 2021;23:185–90.

    Article  PubMed  Google Scholar 

  24. Kakadia JH, Jain BB, Biggar K, Sutherland A, Nygard K, Li C, et al. Hyperphosphorylation of fetal liver IGFBP-1 precedes slowing of fetal growth in nutrient-restricted baboons and may be a mechanism underlying IUGR. Am J Physiol Endocrinol Metab. 2020;319:E614–E628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Abu Shehab M, Khosravi J, Han VKM, Shilton BH, Gupta MB. Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance. J Proteome Res. 2010;9:1873–81.

    Article  CAS  PubMed  Google Scholar 

  26. Madeleneau D, Buffat C, Mondon F, Grimault H, Rigourd V, Tsatsaris V, et al. Transcriptomic analysis of human placenta in intrauterine growth restriction. Pediatr Res. 2015;77:799–807.

    Article  CAS  PubMed  Google Scholar 

  27. Martín-Estal I, de la Garza RG, Castilla-Cortázar I. Intrauterine Growth Retardation (IUGR) as a Novel Condition of Insulin-Like Growth Factor-1 (IGF-1) Deficiency. Rev Physiol Biochem Pharmacol. 2016;170:1–35.

    Article  PubMed  Google Scholar 

  28. Giudice LC, Martina NA, Crystal RA, Tazuke S, Druzin M. Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia. Am J Obstet Gynecol. 1997;176:751–7.

    Article  CAS  PubMed  Google Scholar 

  29. Larsson A, Palm M, Basu S, Axelsson O. Insulin-like growth factor binding protein-1 (IGFBP-1) during normal pregnancy. Gynecol Endocrinol. 2013;29:129–32.

    Article  CAS  PubMed  Google Scholar 

  30. Christians JK, Gruslin A. Altered levels of insulin-like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010;30:815–20.

    Article  CAS  PubMed  Google Scholar 

  31. Martina NA, Kim E, Chitkara U, Wathen NC, Chard T, Giudice LC. Gestational age-dependent expression of insulin-like growth factor-binding protein-1 (IGFBP-1) phosphoisoforms in human extraembryonic cavities, maternal serum, and decidua suggests decidua as the primary source of IGFBP-1 in these fluids during early pregnancy. J Clin Endocrinol Metab. 1997;82:1894–8.

    CAS  PubMed  Google Scholar 

  32. Hall K, Hansson U, Lundin G, Luthman M, Persson B, Póvoa G, et al. Serum levels of somatomedins and somatomedin-binding protein in pregnant women with type I or gestational diabetes and their infants. J Clin Endocrinol Metab. 1986;63:1300–6.

    Article  CAS  PubMed  Google Scholar 

  33. Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas. 2002;41:S65–S83.

    Article  CAS  PubMed  Google Scholar 

  34. Prentice RL, Zhao S, Johnson M, Aragaki A, Hsia J, Jackson RD, et al. Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases. Genome Med. 2013;5:112.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes. 2002;51:2629–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Funding

Guangzhou Science, Technology and Innovation Commission (2019GX03).

Author information

Author notes

  1. These authors contributed equally: Xianglan Peng, Dong He

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Center for Reproductive Medicine/Department of Fetal Medicine and Prenatal Diagnosis/BioResource Research Center, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China

    Xianglan Peng, Rui Peng, Jianyang Feng, Dunjin Chen, Qixuan Li, Jiaxiong Zhou & Hong He

  2. Department of Pharmacology, School of Chinese Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China

    Dong He, Hongkai Xie, Yitong Guo & Yang Chen

Authors
  1. Xianglan Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianyang Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dunjin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hongkai Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qixuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yitong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jiaxiong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hong He
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XP and DH conducted the investigation, designation, methodology, data curation, writing (original draft), and writing (review and editing). RP and HX collected the samples and data and assisted in the investigation. JF and DC were responsible for methodology and editing. QL, YG, and JZ collected the samples and data. YC was responsible for resources and supervision. HH was responsible for project administration, resources, and supervision. XP and DH contributed equally to this study. All authors reviewed and approved the final manuscript submitted for publication.

Corresponding authors

Correspondence to Yang Chen or Hong He.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval

The present study was approved by the Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University on 8 August 2014 (REC ref. no.2014 (085)).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, X., He, D., Peng, R. et al. Associations between IGFBP1 gene polymorphisms and the risk of preeclampsia and fetal growth restriction. Hypertens Res 46, 2070–2084 (2023). https://doi.org/10.1038/s41440-023-01309-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-023-01309-8

Keywords

This article is cited by

Search

Advanced search

Quick links